Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q4 Loss of $0.33
ALNY Hot Sheet
Revenue Growth %: -1.4%Financial Fact:
General and administrative: 10.41M
Today's EPS Names:
TARO, BRLI, TLB, More
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q4 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $20.9 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- UPDATE: Lowe's (LOW) Beats Q1 Views Amid Lagging Seasonal Demand; Issues Light FY12 Earnings Outlook
- UPDATE: Auriga Starts Teva Pharma (TEVA) at Hold; Sidelined Until New CEO Is Convincing
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
